Nonerosive Reflux Disease Treatment Demand Propelled by Increasing Incidences of Acid Reflux Disorder and GERD, Opines Fact.MR

Fact.MR, a global research & consulting firm, in their updated edition of the report, states that the nonerosive reflux disease treatment market is likely to foresee a steady CAGR in 2021 & beyond. Increasing clinical studies in NERD treatment are projected to fuel market expansion throughout the forecast period. Cutting-edge drug molecule development in proton pump inhibitor (PPI) class is projected to enhance PPI outcome in nonerosive reflux disease treatment, thus driving the market growth. 

Proton pump inhibitors are therapeutically highly efficient drugs in NERD treatment although whole symptom control is low. On the other hand, H2 – blockers have lower success rate in NERD treatment however are having higher adoption rate. Abbreviated success rate of proton pump inhibitors in patients with heartburn and GERD is accredited to co-existing NERD disease.” states Fact.MR.

Surge in Incidences of Acid Reflux Disorder (Heartburn) are Fuelling the Demand

Around 50-70% patients with GERD as well as about 49% patients with heartburn incline to have nonerosive reflux ailments, therefore growing prevalence of GERD in addition to heartburn ascribing to growth of nonerosive reflux disease treatment industry. Growth of GERD, heartburn and NERD is corresponding to growing prevalence of obesity in addition to other dietary aspects which are contributing to the growth of nonerosive reflux disease treatment. Significant impact on health associated quality of life together with work related productivity is suggestive of more probabilities to develop NERD which in turn fuels NERD treatment market.

Request Sample Report-

Proton Pump Inhibitors will Witness Increase in Demand

Proton pump inhibitors are anticipated to gain traction as a result of few side effects in addition to the widespread adoption. Growing acceptance of novel drug delivery systems and increasing prevalence of peptic ulcer along with other gastro-intestinal disorders are fueling the demand for proton pump inhibitors considerably.

Growing consumer adoption of novel drug delivery systems and introduction of novel products is offering growth prospects for the proton pump inhibitors.

How Big is the Prospect for Nonerosive Reflux Disease Treatment Providers in US?

The US is anticipated to remain the lucrative region due to high prevalence of heartburn and GERD (gastroesophageal reflux disease (around 20%)). Lifestyle correlating to obesity in the US is accountable for snowballing nonerosive reflux disease treatment industry. The UK and Germany is anticipated to be the second biggest regions for nonerosive reflux disease as a result of the increasing commonness of GERD (around 9-17%)

Emerging regions such as India and China (2-5%) are anticipated to witness a steady growth pace for nonerosive reflux disease treatment.

Request Customized Report

Consistent Launching of New Product and Partnerships Remains Prime Focus Areas: Fact.MR Survey

The nonerosive reflux disease treatment market is extremely fragmented. Fact.MR’s survey indicated that market players are concentrating on new product launches, agreements, acquisitions, partnerships, joint ventures, and expansions to boost their market presence in 2021 & beyond. The updated edition of the report provides comprehensive coverage of the projected to remain the key strategies of market players. Some of the players profiled in the report are Eisai Co, AstraZeneca plc, GlaxoSmithKline PLC, Johnson & Johnson, Takeda Pharmaceutical Co., Ltd, Daewoong Pharmaceutical Co., Ltd., SRS Pharmaceuticals Pvt. Ltd., Ironwood Pharmaceuticals, Inc. and SFJ Pharmaceuticals Group.The updated edition also offers a detailed analysis of the COVID-19 impact on this market.

Explore Fact.MR’s Healthcare Reports Delve into Fact.MR’s extensive study on the balloon catheter market, offering detailed assessment. The study analyses crucial trends that are currently determining, and those which are expected to shape future expansion trajectory, shedding light on the vital dynamics such as drivers, restraints and opportunities. The global hormone replacement therapy market study published by Fact.MR incorporates detailed assessment of the market landscape, taking into consideration value chain analysis, business execution and supply chain analysis across key markets. Fact.MR’s global optic nerve disorders drugs market research report provides stakeholders with an exhaustive analysis on key market dynamics, such as the drivers, restraints, opportunities and trends responsible for shaping the future expansion trajectory.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in Rockville, United States and Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

Back to news